DE60027717D1 - Orale zusammensetzung zur pilzbehandlung die itraconazol enthält und herstellungsverfahren davon - Google Patents

Orale zusammensetzung zur pilzbehandlung die itraconazol enthält und herstellungsverfahren davon

Info

Publication number
DE60027717D1
DE60027717D1 DE60027717T DE60027717T DE60027717D1 DE 60027717 D1 DE60027717 D1 DE 60027717D1 DE 60027717 T DE60027717 T DE 60027717T DE 60027717 T DE60027717 T DE 60027717T DE 60027717 D1 DE60027717 D1 DE 60027717D1
Authority
DE
Germany
Prior art keywords
oral composition
manufacturing
treatment containing
itraconazole
containing itraconazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60027717T
Other languages
English (en)
Other versions
DE60027717T2 (de
Inventor
Jong Soo Woo
Hong Gi Yi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Pharmaceutical Co Ltd
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of DE60027717D1 publication Critical patent/DE60027717D1/de
Application granted granted Critical
Publication of DE60027717T2 publication Critical patent/DE60027717T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Plant Substances (AREA)
DE60027717T 1999-06-16 2000-06-16 Orale zusammensetzung zur pilzbehandlung die itraconazol enthält und herstellungsverfahren davon Expired - Lifetime DE60027717T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1019990022472A KR100331529B1 (ko) 1999-06-16 1999-06-16 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법
KR9922472 1999-06-16
PCT/KR2000/000637 WO2000076520A1 (en) 1999-06-16 2000-06-16 Antifungal oral composition containing itraconazole and process for preparing same

Publications (2)

Publication Number Publication Date
DE60027717D1 true DE60027717D1 (de) 2006-06-08
DE60027717T2 DE60027717T2 (de) 2007-05-10

Family

ID=36441999

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60027717T Expired - Lifetime DE60027717T2 (de) 1999-06-16 2000-06-16 Orale zusammensetzung zur pilzbehandlung die itraconazol enthält und herstellungsverfahren davon

Country Status (18)

Country Link
US (1) US6039981A (de)
EP (1) EP1185273B1 (de)
JP (1) JP3717849B2 (de)
KR (1) KR100331529B1 (de)
CN (1) CN1170539C (de)
AT (1) ATE324893T1 (de)
AU (1) AU754300B2 (de)
CA (1) CA2376706C (de)
CZ (1) CZ292146B6 (de)
DE (1) DE60027717T2 (de)
ES (1) ES2262517T3 (de)
HU (1) HUP0201533A3 (de)
MX (1) MXPA01012739A (de)
RS (1) RS50008B (de)
RU (1) RU2216323C2 (de)
SI (1) SI20677A (de)
TR (1) TR200103681T2 (de)
WO (1) WO2000076520A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0862463A1 (de) 1995-11-23 1998-09-09 Janssen Pharmaceutica N.V. Feste mischungen von cyclodextrinen, hergestellt durch schmelzextrusionsverfahren
GB9720061D0 (en) * 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
KR100331529B1 (ko) * 1999-06-16 2002-04-06 민경윤 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법
CA2291346A1 (en) * 1999-11-26 2001-05-26 Bernard Charles Sherman Antifungal solutions
GB0015239D0 (en) * 2000-06-21 2000-08-16 Biochemie Gmbh Organic compounds
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US6869617B2 (en) * 2000-12-22 2005-03-22 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
BR0116377A (pt) * 2000-12-22 2005-12-13 Baxter Int Métodos para preparar partìculas submicronicamente dimensionadas de um composto orgânico, e para preparar uma suspensão de um composto farmaceuticamente ativo, e, composição de matéria
KR100435141B1 (ko) * 2000-12-28 2004-06-09 한미약품 주식회사 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법
US6673373B2 (en) * 2001-02-01 2004-01-06 Carlsbad Technology Inc. Antifungal formulation and the methods for manufacturing and using the same
US6663897B2 (en) 2001-02-06 2003-12-16 Dsm Ip Assets B.V. Oral itraconazole formulations and methods of making the same
EP1842532A3 (de) * 2001-02-06 2009-04-22 Stiefel Laboratories, Inc. Orale, schwer wasserlösliche antimykotische Formulierungen und Verfahren zu deren Herstellung
KR100455216B1 (ko) * 2001-06-27 2004-11-09 한미약품 주식회사 난용성 항진균제의 경구투여용 조성물 및 이의 제조 방법
US8071133B2 (en) * 2001-08-20 2011-12-06 Stiefel Laboratories, Inc. Oral dosage forms of water insoluble drugs and methods of making the same
KR100425755B1 (ko) * 2001-08-27 2004-04-03 주식회사 원진신약 이트라코나졸을 함유하는 조성물 및 그 제조방법
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
MXPA04002446A (es) * 2001-09-26 2004-07-23 Baxter Int Preparacion de nanoparticulas de tamano de submicras mediante dispersion y remocion de la fase liquida o solvente.
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
CA2363376A1 (en) * 2001-11-16 2003-05-16 Bernard Charles Sherman Solid pharmaceutical compositions for oral administration comprising itraconazole
KR100441745B1 (ko) * 2001-11-30 2004-07-27 환인제약 주식회사 이트라코나졸의 경구투여용 조성물과 그 제조방법
US20040115266A1 (en) * 2002-02-01 2004-06-17 Namburi Ranga Raju Oral itraconazole formulations and methods of making the same
US20040266776A1 (en) 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
WO2004009120A1 (en) * 2002-07-22 2004-01-29 Nanohybrid Co., Ltd. Hybrid of itraconazole, cyclosporine or carvedilol with a layered silicate and a process for preparing the same
US20050058670A1 (en) * 2003-09-09 2005-03-17 Jong-Soo Woo Oral itraconazole composition which is not affected by ingested food and process for preparing same
CA2540984C (en) * 2003-10-10 2011-02-08 Lifecycle Pharma A/S A solid dosage form comprising a fibrate
JP2007508249A (ja) * 2003-10-10 2007-04-05 ライフサイクル ファーマ アクティーゼルスカブ フィブラートとスタチンを含む固体剤型
US9173847B2 (en) * 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
US20050118265A1 (en) * 2003-11-28 2005-06-02 Anandi Krishnan Antifungal oral dosage forms and the methods for preparation
JP2005239696A (ja) * 2004-01-30 2005-09-08 Daiichi Suntory Pharma Co Ltd 無機物質を配合した医薬硬質カプセル剤
US20050196416A1 (en) * 2004-02-05 2005-09-08 Kipp James E. Dispersions prepared by use of self-stabilizing agents
CN1294912C (zh) * 2004-03-01 2007-01-17 上海医药工业研究院 伊曲康唑盐酸盐组合物及其冻干粉针
KR20050119397A (ko) * 2004-06-16 2005-12-21 보람제약주식회사 고상용해를 이용한 난용성 약물의 가용화 방법과 이를이용한 가용화 조성물
EP1765350B1 (de) * 2004-06-24 2011-05-18 CTC Bio, Inc. Herstellungsverfahren für eine feste dispersion mit itraconazol
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
US20070134341A1 (en) * 2005-11-15 2007-06-14 Kipp James E Compositions of lipoxygenase inhibitors
MY157620A (en) * 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
GB0612809D0 (en) * 2006-06-28 2006-08-09 Univ Sunderland Formulation
US20090152176A1 (en) * 2006-12-23 2009-06-18 Baxter International Inc. Magnetic separation of fine particles from compositions
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
GB0714670D0 (en) * 2007-07-27 2007-09-05 Ineos Healthcare Ltd Use
GB0720220D0 (en) * 2007-10-16 2007-11-28 Ineos Healthcare Ltd Compound
GB0720716D0 (en) * 2007-10-23 2007-12-05 York Pharma Plc Novel formulation
GB0913525D0 (en) 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
GB201001779D0 (en) 2010-02-04 2010-03-24 Ineos Healthcare Ltd Composition
US10736891B2 (en) * 2016-01-07 2020-08-11 Roy MADIGAN Composition and method for treating chagas disease
CN110755369A (zh) * 2019-10-30 2020-02-07 天津市保灵动物保健品有限公司 一种伊曲康唑软膏及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07503953A (ja) * 1992-02-12 1995-04-27 ジヤンセン・シラグ・ソチエタ・ペル・アチオニ リポソームイトラコナゾール組成物
WO1994016701A1 (en) * 1993-01-27 1994-08-04 Sepracor, Inc. Methods and compositions of (2s,4r) itraconazole for treating fungal yeast and dermatophyte infections
WO1994016700A1 (en) * 1993-01-27 1994-08-04 Sepracor, Inc. Method and composition employing (2r,4s) itraconazole
US5750147A (en) * 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
EE03902B1 (et) * 1996-05-20 2002-12-16 Janssen Pharmaceutica N.V. Osakesed, nende valmistamismeetod ja kasutamine, farmatseutiline doseerimisvorm ja selle valmistamismeetod, tahke dispersioon ning farmatseutiline pakend
KR100321617B1 (ko) * 1997-06-16 2002-07-27 동아제약 주식회사 항진균제와 유기산류의 공융혼합물 및 이를 함유하는 약학적 제제
KR100367483B1 (ko) * 1997-12-19 2003-03-26 동아제약 주식회사 당류를이용하여용해도및용해속도를증가시킨이트라코나졸경구용조성물및그제조방법
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
KR100331529B1 (ko) * 1999-06-16 2002-04-06 민경윤 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법

Also Published As

Publication number Publication date
KR100331529B1 (ko) 2002-04-06
EP1185273A1 (de) 2002-03-13
EP1185273B1 (de) 2006-05-03
SI20677A (sl) 2002-04-30
CN1170539C (zh) 2004-10-13
RS50008B (sr) 2008-09-29
ATE324893T1 (de) 2006-06-15
DE60027717T2 (de) 2007-05-10
WO2000076520A1 (en) 2000-12-21
AU5114400A (en) 2001-01-02
CA2376706C (en) 2006-06-06
ES2262517T3 (es) 2006-12-01
JP2003501475A (ja) 2003-01-14
HUP0201533A2 (en) 2002-09-28
RU2216323C2 (ru) 2003-11-20
HUP0201533A3 (en) 2006-07-28
AU754300B2 (en) 2002-11-14
CZ20014508A3 (cs) 2003-03-12
EP1185273A4 (de) 2004-03-10
YU88601A (sh) 2004-07-15
CA2376706A1 (en) 2000-12-21
MXPA01012739A (es) 2002-07-02
JP3717849B2 (ja) 2005-11-16
US6039981A (en) 2000-03-21
CN1390127A (zh) 2003-01-08
CZ292146B6 (cs) 2003-08-13
KR20010002590A (ko) 2001-01-15
TR200103681T2 (tr) 2002-05-21

Similar Documents

Publication Publication Date Title
DE60027717D1 (de) Orale zusammensetzung zur pilzbehandlung die itraconazol enthält und herstellungsverfahren davon
SG158731A1 (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
DE69921941D1 (de) Verfahren zur Herstellung von pharmazeutischen Wirkstoffpartikeln
BR0210855A (pt) Método de fabricação de formulações de liberação prolongada
EE200300329A (et) Meetod peroraalselt manustatavate epotiloonide biosaadavuse suurendamiseks ning selles kasutatav komplekt, ravimkoostis ja farmatseutiline ravimvorm
DE60335560D1 (de) Zusammensetzungen enthaltend zitronensäure zur behandlung von nagelpilzerkrankungen
EP1416961A4 (de) Zusammensetzung und verfahren zur behandlung von krankheiten
ATE494884T1 (de) Oxidative zusammensetzung zur behandlung von keratinfasern, die spezielle aminosilikone enthält
ATE389401T1 (de) Verfahren zur herstellung von pharmazeutischen zusammensetzungen enthaltend epothilon-analoga zur krebsbehandlung
EP1392293A4 (de) Verfahren zur behandlung von tumoren mit nordihydroguaiaretinsäurederivaten
TR200201638T2 (tr) Yeni imidazo[1,3,5]triazinonlar ve kullanımları
DE60210552D1 (de) Prozess zur Herstellung einer festen pharmazeutischen Zubereitung welche einen schwerlöslichen Wirkstoff enthält
ATE282405T1 (de) Sterolester in tablettierter fester arzneiform
EP1324732A4 (de) Körperverträgliche oraler wundverband anwendung und herstellungsverfahren
SI1590144T1 (sl) Postopek za pripravo biološko aktivnih formulacij
BR9904036A (pt) Combinação de ìons de zinco e vitamina c e processo de fabricação
DE60215313D1 (de) Indolderivate und deren verwendung als gnrh antagonisten
DE60129829D1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
DK1189627T3 (da) Sammensætninger indeholdende opløselige former af HLA-G til behandling af inflammatoriske patologiske tilstande i huden
DE60120990D1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
GB0111594D0 (en) Pipecolnic acid derivatives method of manufacturing the same and therapeutic agents containing these compounds
ATE250578T1 (de) Indenoindolon-derivate, verfahren zu ihrer herstellung und die enthaltenden pharmazeutischen zusammensetzungen
NO20033147L (no) Fremgangsmåte for fremstilling av rent ondansetronhydrogenklorid-dihydrat
ATE269849T1 (de) Verfahren zur herstellung von (3-cyano-1h-indol-7-yl)(4-(4-fluorphenethyl)pip razin-1-yl)methanon und dessen salzen
DE60043648D1 (de) Medikamente zur behandlung von periodontalen erkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition